Literature DB >> 26292621

Functional autoantibodies in systemic sclerosis.

Jeannine Günther1, Judith Rademacher, Jakob M van Laar, Elise Siegert, Gabriela Riemekasten.   

Abstract

Functional autoantibodies are an emerging field of research that focuses on the effects of these immunoglobulins when they bind to their target molecules. Accumulating information now exists about the molecular targets and precise binding mechanisms of functional autoantibodies as well as about their downstream effects. These data raise the need to distinguish functional autoantibodies from non-functional autoantibodies with regard to their ability to stimulate or to inhibit their target protein via binding. The presence of autoantibodies has been documented in autoimmune disorders decades ago, but meanwhile, more and more autoantibodies have been identified as functional, acting as pathogenic drivers involved in the induction of organ-specific damage in systemic sclerosis as well as in other autoimmune disorders. These findings offer new opportunities for the development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26292621     DOI: 10.1007/s00281-015-0513-5

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  112 in total

1.  Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.

Authors:  J Tillon; F Hervé; D Chevallier; J-F Muir; H Levesque; I Marie
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

Review 2.  Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance.

Authors:  P Klein-Weigel; C Opitz; G Riemekasten
Journal:  Vasa       Date:  2011-01       Impact factor: 1.961

3.  Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies.

Authors:  Yasuhito Hamaguchi; Masanari Kodera; Takashi Matsushita; Minoru Hasegawa; Yuki Inaba; Toshikazu Usuda; Masataka Kuwana; Kazuhiko Takehara; Manabu Fujimoto
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

4.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

Review 5.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

6.  Estrogen alters thresholds for B cell apoptosis and activation.

Authors:  Christine M Grimaldi; James Cleary; A Selma Dagtas; Dariush Moussai; Betty Diamond
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

7.  Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.

Authors:  Maurizio Cutolo; Barbara Ruaro; Carmen Pizzorni; Francesca Ravera; Vanessa Smith; Giuseppe Zampogna; Sabrina Paolino; Bruno Seriolo; Marco Cimmino; Alberto Sulli
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

8.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

9.  Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression.

Authors:  Antonello Giovannetti; Angela Maselli; Tania Colasanti; Edoardo Rosato; Felice Salsano; Simonetta Pisarri; Ivano Mezzaroma; Walter Malorni; Elena Ortona; Marina Pierdominici
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

Review 10.  Infectome: a platform to trace infectious triggers of autoimmunity.

Authors:  Dimitrios P Bogdanos; Daniel S Smyk; Pietro Invernizzi; Eirini I Rigopoulou; Miri Blank; Shideh Pouria; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2012-12-22       Impact factor: 9.754

View more
  13 in total

Review 1.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 2.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 3.  Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.

Authors:  Mary Carmelle Philogene; Tory Johnson; Arthur Jason Vaught; Sammy Zakaria; Neal Fedarko
Journal:  Hum Immunol       Date:  2019-04-19       Impact factor: 2.850

Review 4.  Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis.

Authors:  Jean-Luc Senécal; Sabrina Hoa; Roger Yang; Martial Koenig
Journal:  J Scleroderma Relat Disord       Date:  2019-09-09

5.  Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.

Authors:  Xia Gao; Guiquan Jia; Anna Guttman; Daryle J DePianto; Katrina B Morshead; Kai-Hui Sun; Nandhini Ramamoorthi; Jason A Vander Heiden; Zora Modrusan; Paul J Wolters; Angelika Jahreis; Joseph R Arron; Dinesh Khanna; Thirumalai R Ramalingam
Journal:  Cell Rep Med       Date:  2020-11-17

6.  Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.

Authors:  Florian Weigold; Jeannine Günther; Moritz Pfeiffenberger; Otavio Cabral-Marques; Elise Siegert; Duska Dragun; Aurélie Philippe; Ann-Katrin Regensburger; Andreas Recke; Xinhua Yu; Frank Petersen; Rusan Catar; Robert Biesen; Falk Hiepe; Gerd R Burmester; Harald Heidecke; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2018-03-22       Impact factor: 5.156

7.  Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?

Authors:  Claudio Corallo; Sara Cheleschi; Maurizio Cutolo; Stefano Soldano; Antonella Fioravanti; Nila Volpi; Daniela Franci; Ranuccio Nuti; Nicola Giordano
Journal:  Arthritis Res Ther       Date:  2019-06-24       Impact factor: 5.156

8.  Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Authors:  An-Sofie Schelpe; Elien Roose; Bérangère S Joly; Inge Pareyn; Ilaria Mancini; Marina Biganzoli; Hans Deckmyn; Jan Voorberg; Rob Fijnheer; Flora Peyvandi; Simon F De Meyer; Paul Coppo; Agnès Veyradier; Karen Vanhoorelbeke
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

9.  Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014.

Authors:  Charles F Dillon; Michael H Weisman; Frederick W Miller
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

Review 10.  Shared and distinct mechanisms of fibrosis.

Authors:  Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2019-11-11       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.